Resolute Onyx™ drug-eluting stent (DES) is a stent and balloon catheter delivery system designed to be placed inside a diseased coronary artery to keep the artery open so that blood can access the heart.Contact Us
Resolute Onyx DES is composed of a single wire strand formed into a continuous sinusoidal waveform, providing a fluid range of motion with greater flexibility and conformability when compared to laser-cut stents.‡
vs. Laser-cut design
Single wire design increases deliverability, flexibility, conformability, wall-apposition, and may reduce arterial injury and thrombus formation.‡1
Sinusoid formed wire
Higher is Better
Resolute Onyx DES is designed with rounded struts that may create a smooth passage for side branch access.‡
Square Strut Cross-Section
Regular Cell Shape
Resolute Onyx DES
Irregular Cell Shape
Xience Sierra™* DES
The Resolute Onyx DES broad size matrix optimizes stent deployment and expansion.
5.75 mm maximum expansion for 4.50 and 5.00 mm sizes§
3.25 mm maximum expansion for 2.0 mm sizes§
Watch a short video to learn more about the BioLinx polymer.
The Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk1, as well as rapid, complete, and functional endothelial healing.||
The 1-month OCT Study investigated early vessel healing in patients with complex coronary artery disease treated with Resolute Onyx DES.
92.3% Stent Coverage at 1 Month2
Resolute Onyx DES is not currently indicated for high bleeding risk patients on 1-month DAPT.
Medtronic and Medtronic logo are trademarks of Medtronic. Third-party trademarks ("™*") belong to their respective owners. All other brands are trademarks of a Medtronic entity.
Including Resolute Integrity DES, part of the Medtronic DES portfolio
Bench test data on file at Medtronic. Bench test data may not be indicative of clinical performance.
Resolute Onyx™ stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Post-dilation required for overexpansion.
In porcine models. Based on test data on file at Medtronic. May not be indicative of clinical performance.
Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. August 1, 2014;35(29):1949-1956.
Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.